Stereotaxis (NYSE:STXS), a global leader in endovascular surgical robotics, announced on Tuesday, January 6, 2026, that it has received U.S. Food and Drug Administration (FDA) approval for its MAGiC™ Magnetic Interventional Ablation Catheter.
This regulatory milestone introduces the first robotically-navigated magnetic ablation catheter to the U.S. market in nearly two decades, specifically designed to perform minimally invasive cardiac ablation for complex arrhythmias.
The MAGiC catheter is indicated for use in adult patients with supraventricular tachycardia (SVT)—including atrioventricular nodal reentrant tachycardia and macroreentrant atrial tachycardia—particularly those with congenital heart disease (CHD).
In these patients, anatomical abnormalities or previous surgical interventions often make conventional manual catheter navigation extremely difficult.
By using computer-controlled magnetic fields, MAGiC offers a level of stability and maneuverability that allows electrophysiologists to reach previously inaccessible areas of the heart with "robotic precision."
This approval follows the successful 2025 launch of the MAGiC Sweep™ mapping catheter and the GenesisX robotic system.
Together, they form an integrated ecosystem that provides high-density mapping and therapeutic ablation within a single robotic platform.
With Stereotaxis technology already utilized in over 150,000 patients globally, the commercial launch of MAGiC in the U.S. is expected to significantly expand access to life-saving care for underserved and complex cardiac populations.